Beam Therapeutics logo

Beam Therapeutics

BEAM | NASDAQ
Chart Builder DCF Calculator
$20.94
-$1.89 (-8.28%)
At close: Nov 16, 2026, 4:00 PM ET
$21.10
+$0.16 (+0.76%)
After-hours: Nov 16, 2026, 7:55 PM ET
-8.28%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
38.7
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #563/1021 (Top 55%)

Key Statistics

Market Data

Market Cap $2.17B
1D Range
20.66 22.70
52W Range
20.60 37.92

Valuation (TTM)

PE -20.13
PB 2.27
EV/EBITDA -14.05

Valuation (NTM)

Forward PE N/A
Forward PEG -2.48
Price Target $79.50
Loading financial charts...

Profile

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle...

Sector Healthcare
Industry Biotechnology
Employees 540
IPO Date Feb 6, 2020
Fiscal Year January - December

Latest News

Beam Therapeutics: Market Selling Promising Data Readouts Doesn't Add Up

4 days ago · seekingalpha.com

Beam Therapeutics: Market Selling Promising Data Readouts Doesn't Add Up
BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study

5 days ago · zacks.com

BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease

6 days ago · globenewswire.com

Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates

14 days ago · zacks.com

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
3 Promising Genomics Stocks to Add to Your Portfolio Now

18 days ago · zacks.com

3 Promising Genomics Stocks to Add to Your Portfolio Now
Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?

19 days ago · zacks.com

Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript

21 days ago · seekingalpha.com

Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript
Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance

21 days ago · marketbeat.com

Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress

21 days ago · globenewswire.com

Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?

1 month ago · fool.com

Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?

Earnings

Latest Earnings
Nov 3, 2026
EPS
-$1.28
Miss -11.30%
REV
$307K
Miss -96.49%
Next Earnings
Feb 23, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
8
Consensus
Buy
Price Target
$79.50
Upside
+279.66%
Buy (7)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.